GSK-owned ViiV Healthcare's Cabenuva Succeeds in Late-Stage HIV Trial
ViiV Healthcare, a joint venture owned by GSK and Shionogi, announced that its long-acting HIV treatment, Cabenuva, successfully completed a late-stage clinical trial. The Phase 3b CROWN study demonstrated the drug's effectiveness, reinforcing ViiV’s position in the competitive HIV therapy market. The success of this trial is significant as it supports potential regulatory approvals and broader adoption of Cabenuva among patients seeking long-term treatment options with fewer dosing requirements. This outcome could enhance GSK and Shionogi’s revenue streams from their stake in ViiV Healthcare, particularly within the growing HIV management sector. The results are likely to be viewed positively by investors due to the potential for increased market share and improved patient outcomes.
